Cue Biopharma downsizes to focus on autoimmune pipeline
The company has fired 25% of its staff and will look for partnerships to further its oncology candidates.
Autoimmune Disorders
Sandoz launches ustekinumab biosimilar in Europe
Boehringer Ingelheim offers Humira biosimilar at 92% discount
SciRhom secures $70m for autoimmune diseases treatments
J&J looks to challenge argenx’s Vyvgart with positive Phase III data
Novo Holdings-backed Commit launches with $17.2m in seed funding
Zenas raises $200m to advance autoimmune antibody therapy
Sanofi gears up for approval of its BTK inhibitor, meets Phase III endpoint
